D Scott McMeekin
Overview
Explore the profile of D Scott McMeekin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
2146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
McMeekin D, Sill M, Walker J, Moore K, Waggoner S, Thaker P, et al.
Gynecol Oncol
. 2015 May;
138(1):36-40.
PMID: 25958319
Objective: To determine the maximum tolerated dose (MTD) of a modified paclitaxel/doxorubicin/cisplatin (TAP) regimen which incorporated intraperitoneal (IP) paclitaxel or IP paclitaxel/cisplatin in advanced endometrial cancer. Methods: Patients (pts) with...
12.
Powell M, Sill M, Goodfellow P, Benbrook D, Lankes H, Leslie K, et al.
Gynecol Oncol
. 2014 Jul;
135(1):38-43.
PMID: 25019571
Purpose: Brivanib, an oral, multi-targeted tyrosine kinase inhibitor with activity against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR) was investigated as a single agent in a...
13.
Gunderson C, Thomas E, Slaughter K, Farrell R, Ding K, Farris R, et al.
Gynecol Oncol
. 2014 May;
134(1):73-7.
PMID: 24793732
Objective: The aim of this study is to evaluate the effect of venous thromboembolism (VTE) chronology with respect to surgery on survival with epithelial ovarian cancer (EOC). Methods: An IRB...
14.
Slaughter K, Thai T, Penaroza S, Benbrook D, Thavathiru E, Ding K, et al.
Gynecol Oncol
. 2014 Apr;
133(1):11-5.
PMID: 24680585
Objective: There is a lack of reliable indicators to predict who will benefit most from anti-angiogenic therapy, such as bevacizumab. Recognizing obesity is associated with increased levels of VEGF, the...
15.
Landrum L, Nugent E, Zuna R, Syzek E, Mannel R, Moore K, et al.
Gynecol Oncol
. 2013 Nov;
132(1):50-4.
PMID: 24219982
Objective: To determine the progression free survival (PFS), toxicity, and patterns of failure for early stage, high-intermediate risk (H-IR) patients in a phase II trial with adjuvant vaginal cuff brachytherapy...
16.
Slaughter K, Nugent E, Bishop E, Perry L, McMeekin D, Moore K
Gynecol Oncol
. 2013 Sep;
132(1):231-5.
PMID: 24041878
Objectives: Previous reviews of phase I clinical trials report limited response rates. Development of novel biologic agents and trials designs have increased these rates. A contemporary appraisal of phase I...
17.
Gunderson C, Farrell R, Dinh B, Thomas E, Vesely S, Lauer J, et al.
Gynecol Oncol
. 2013 Jun;
130(3):411-5.
PMID: 23791827
Objective: This study aimed to evaluate the utility of risk stratification of gynecologic oncology patients with neutropenic fever (NF). Methods: A retrospective chart review of gynecologic cancer patients admitted with...
18.
Gunderson C, Nugent E, McMeekin D, Moore K
Int J Gynecol Cancer
. 2013 Jun;
23(6):1099-103.
PMID: 23765207
Objective: To evaluate the impact of distance from residence to treatment center on disease characteristics and recurrence of cervical cancer. Materials And Methods: A single-institution retrospective chart review of patients...
19.
Brinton L, Felix A, McMeekin D, Creasman W, Sherman M, Mutch D, et al.
Gynecol Oncol
. 2013 Mar;
129(2):277-84.
PMID: 23485770
Objective: Although the epidemiology of typical endometrial carcinomas (grades 1-2 endometrioid or Type I) is well established, less is known regarding higher grade endometrioid or non-endometrioid carcinomas (Type II). Within...
20.
Coleman R, Sill M, Lankes H, Fader A, Finkler N, Hoffman J, et al.
Gynecol Oncol
. 2012 Aug;
127(3):538-43.
PMID: 22922531
Objectives: Aflibercept targets vascular endothelial growth factor and placental growth factor. We evaluated activity and toxicity of aflibercept in recurrent/persistent endometrial cancer patients. Biomarkers and association with clinical characteristics and...